Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment

Turn Therapeutics Inc.

Turn Therapeutics Inc.

TTRX

0.00
  • Turn Therapeutics flagged peer-reviewed results already published on GX-03 in an IL-36-associated murine dermatitis model.
  • The study showed GX-03 reduced visible disease severity versus no treatment, supporting activity in an inflammation setting linked to skin barrier disruption.
  • No treatment-related safety issues were observed in the animal study.
  • The publication underpins GX-03’s Phase 2 program in moderate-to-severe atopic dermatitis, supporting a localized, non-systemic development strategy.
  • A follow-on mechanistic manuscript is under review, with additional publications planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605270805BIZWIRE_USPR_____20260527_BW251995) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.